Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTLNASDAQ:BCDANASDAQ:BGXXNASDAQ:CLRB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTLArtelo Biosciences$0.95-0.2%$0.96$0.82▼$1.59$3.13M1.03134,015 shs11,504 shsBCDABioCardia$1.97+3.7%$2.32$1.63▼$5.69$10.20M0.91288,853 shs30,862 shsBGXXBright Green$0.05$0.03▼$0.54$11.47M-0.26360,154 shs25,935 shsCLRBCellectar Biosciences$0.25-1.2%$0.29$0.22▼$3.42$11.48M0.481.14 million shs344,587 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTLArtelo Biosciences+0.24%+1.60%-17.67%-17.67%-37.38%BCDABioCardia+1.06%-18.10%+7.95%-17.75%-59.05%BGXXBright Green0.00%0.00%0.00%+53.85%-73.90%CLRBCellectar Biosciences+1.20%-0.67%-16.78%-19.75%-92.13%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARTLArtelo Biosciences2.3177 of 5 stars3.84.00.00.00.60.01.3BCDABioCardia2.7742 of 5 stars3.83.00.00.01.92.50.6BGXXBright GreenN/AN/AN/AN/AN/AN/AN/AN/ACLRBCellectar Biosciences2.3066 of 5 stars3.25.00.00.02.50.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTLArtelo Biosciences 3.50Strong Buy$5.50477.31% UpsideBCDABioCardia 3.50Strong Buy$25.001,169.04% UpsideBGXXBright Green 0.00N/AN/AN/ACLRBCellectar Biosciences 2.33Hold$12.504,918.07% UpsideCurrent Analyst Ratings BreakdownLatest ARTL, CLRB, BGXX, and BCDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025CLRBCellectar BiosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/28/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.004/2/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/4/2025ARTLArtelo BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.002/27/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00(Data available from 5/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTLArtelo BiosciencesN/AN/AN/AN/A$4.12 per shareN/ABCDABioCardia$58K175.87N/AN/A($1.11) per share-1.77BGXXBright GreenN/AN/AN/AN/A$0.06 per shareN/ACLRBCellectar BiosciencesN/AN/AN/AN/A($0.96) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTLArtelo Biosciences-$9.29M-$2.99N/AN/AN/AN/A-104.59%-94.06%N/ABCDABioCardia-$11.57M-$2.33N/AN/AN/A-1,999.77%N/A-208.38%N/ABGXXBright Green-$13.13M-$0.06N/AN/AN/AN/A-88.37%-55.30%N/ACLRBCellectar Biosciences-$42.77M-$0.73N/AN/AN/AN/AN/A-191.22%8/11/2025 (Estimated)Latest ARTL, CLRB, BGXX, and BCDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025BCDABioCardia-$0.39-$0.59-$0.20-$0.59N/AN/A5/13/2025Q1 2025ARTLArtelo Biosciences-$0.13-$0.72-$0.59-$0.72N/AN/A5/13/2025Q1 2025CLRBCellectar Biosciences-$0.17-$0.13+$0.04-$0.14N/AN/A3/26/2025Q4 2024BCDABioCardia-$0.87-$0.25+$0.62-$0.25$0.02 million$0.02 million3/3/2025Q4 2024ARTLArtelo Biosciences-$0.74-$1.17-$0.43-$1.17N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTLArtelo BiosciencesN/AN/AN/AN/AN/ABCDABioCardiaN/AN/AN/AN/AN/ABGXXBright GreenN/AN/AN/AN/AN/ACLRBCellectar BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTLArtelo BiosciencesN/A7.157.15BCDABioCardiaN/A1.781.78BGXXBright GreenN/A0.010.01CLRBCellectar BiosciencesN/A1.771.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTLArtelo Biosciences0.87%BCDABioCardia20.57%BGXXBright Green7.83%CLRBCellectar Biosciences16.41%Insider OwnershipCompanyInsider OwnershipARTLArtelo Biosciences0.83%BCDABioCardia20.00%BGXXBright Green62.55%CLRBCellectar Biosciences3.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTLArtelo Biosciences53.28 million3.20 millionNot OptionableBCDABioCardia405.18 million3.67 millionOptionableBGXXBright Green2191.17 million71.59 millionNo DataCLRBCellectar Biosciences1046.08 million44.38 millionOptionableARTL, CLRB, BGXX, and BCDA HeadlinesRecent News About These CompaniesWall Street Zen Initiates Coverage on Cellectar Biosciences (NASDAQ:CLRB)May 23 at 2:17 AM | americanbankingnews.com4 Medical Product Stocks to Watch From a Challenging IndustryMay 21 at 12:41 PM | zacks.comRoth Capital Brokers Increase Earnings Estimates for CLRBMay 17, 2025 | americanbankingnews.comCellectar Biosciences (NASDAQ:CLRB) Receives Hold Rating from Maxim GroupMay 16, 2025 | americanbankingnews.comMaxim Group Downgrades Cellectar Biosciences (CLRB)May 15, 2025 | msn.comCellectar Biosciences, Inc. (NASDAQ:CLRB) Q1 2025 Earnings Call TranscriptMay 14, 2025 | insidermonkey.comCellectar Biosciences Inc (CLRB) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...May 14, 2025 | finance.yahoo.comCellectar Biosciences Inc. (CLRB) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comCellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate UpdateMay 13, 2025 | globenewswire.comCellectar Biosciences (NASDAQ:CLRB) Earns Sell Rating from Analysts at StockNews.comMay 13, 2025 | americanbankingnews.comInsights Ahead: Cellectar Biosciences's Quarterly EarningsMay 12, 2025 | benzinga.comCellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025May 7, 2025 | globenewswire.comCellectar explores strategic options to enhance shareholder valueMay 3, 2025 | uk.investing.comCellectar is seeking strategic alternatives, sinking stockApril 30, 2025 | fiercebiotech.comCellectar Announces Plan to Explore Strategic AlternativesApril 30, 2025 | globenewswire.com4 Medical Product Stocks to Buy From a Challenging IndustryApril 17, 2025 | zacks.comIs Cellectar Biosciences (CLRB) Stock Outpacing Its Medical Peers This Year?March 18, 2025 | zacks.comCellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call TranscriptMarch 15, 2025 | seekingalpha.comOppenheimer Keeps Their Hold Rating on Cellectar Biosciences (CLRB)March 14, 2025 | markets.businessinsider.comCellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2024 Earnings Call TranscriptMarch 14, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARTL, CLRB, BGXX, and BCDA Company DescriptionsArtelo Biosciences NASDAQ:ARTL$0.95 0.00 (-0.24%) Closing price 03:47 PM EasternExtended Trading$0.97 +0.02 (+1.82%) As of 04:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.BioCardia NASDAQ:BCDA$1.97 +0.07 (+3.68%) Closing price 04:00 PM EasternExtended Trading$2.12 +0.15 (+7.61%) As of 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.Bright Green NASDAQ:BGXXBright Green Corporation focuses on the cultivation, manufacture, and sale of cannabis and cannabis-related products. Its products are used in research, pharmaceutical applications, and affiliated exports. The company was incorporated in 2019 and is based in Grants, New Mexico.Cellectar Biosciences NASDAQ:CLRB$0.25 0.00 (-1.15%) Closing price 04:00 PM EasternExtended Trading$0.25 +0.00 (+1.97%) As of 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
